Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Scherrer, Alexandra U ^a   Böni, Jürg ^b   Yerly, Sabine ^c   Klimkait, Thomas ^d   Aubert, Vincent ^e   Furrer, Hansjakob ^f   Calmy, Alexandra ^c   Cavassini, Matthias ^e   Elzi, Luigia ^g   Vernazza, Pietro L ^h   Bernasconi, Enos ⁱ   Ledergerber, Bruno ^a   Günthard, Huldrych F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; RISK ASSESSMENT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84870015697     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050307     Document Type: Article

References (43)

1. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, et al. (2006) Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 3: e356.
2. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, et al. (2007) Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 21: 721-732.
3. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, et al. (2009) Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 49: 1928-1935.
4. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, et al. (2005) HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 40: 34-40.
5. Reynolds SJ, Kityo C, Mbamanya F, Dewar R, Ssali F, et al. (2009) Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther 14: 293-297.
6. Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, et al. (2004) Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 18: 1503-1511.
7. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, et al. (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11: 363-371.
8. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
9. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, et al. (2008) Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 22: 2097-2106.
10. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, et al. (2009) Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 9: 409-417.
11. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, et al. (2011) Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 53: 1283-1290.
12. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, et al. (2008) Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371: 1443-1451.
13. Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, et al. (2010) Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 39: 1179-1189.
14. von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, et al. (2007) Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 167: 1782-1790.
15. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164.
16. Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, et al. (2006) Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 41: 385-392.
17. Cole SR, Napravnik S, Mugavero MJ, Lau B, Eron JJ Jr, et al. (2010) Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol 171: 198-205.
18. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, et al. (2003) Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349: 2304-2315.
19. MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, et al. (2006) A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 368: 2125-2135.
20. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, et al. (2011) Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 154: 445-456.
21. Gupta R, Hill A, Sawyer AW, Pillay D, (2008) Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 47: 712-722.
22. Babiker A, Castronee Green H, Compagnucci A, Fiscus S, Giaquinto C, et al. (2011) First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 11: 273-283.
23. Bartlett JA, Buda JJ, von Scheele B, Mauskopf JA, Davis EA, et al. (2006) Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr 41: 323-331.
24. Mtambo A, Chan K, Shen A, Lima V, Hogg R, et al. (2012) Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings. HIV Med 13: 141-147.
25. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106.
26. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, et al. (2009) The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23: 1127-1134.
27. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, et al. (2007) Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 44: 447-452.
28. Murillo W, de Rivera IL, Parham L, Jovel E, Palou E, et al. (2010) Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med 11: 95-103.
29. Wallis CL, Papathanasopolous MA, Fox M, Conradie F, Ive P, et al. (2012) Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther 17: 313-320.
30. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, et al. (2003) Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 188: 1433-1443.
31. Metzner KJ, Allers K, Rauch P, Harrer T, (2007) Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS 21: 703-711.
32. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305: 1327-1335.
33. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. (2009) Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 199: 693-701.
34. van de Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, et al. (2006) The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41: 352-360.
35. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, et al. (2008) Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65: 65-70.
36. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, et al. (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477: 95-98.
37. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, et al. (2005) Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A 102: 2093-2098.
38. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ Jr, et al. (2007) Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci U S A 104: 317-322.
39. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, et al. (2007) N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 4: e335.
40. Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, et al. (2008) Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 82: 3261-3270.
41. Metzner KJ, Rauch P, von Wyl V, Leemann C, Grube C, et al. (2010) Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 201: 1063-1071.
42. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ, (2009) Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 52: 209-221.
43. Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, et al. (2010) Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr 55: 336-344.